Arrowhead Pharmaceuticals (ARWR) Highlights RNAi Advances at December 2024 Healthcare Conferences

Arrowhead Pharmaceuticals Showcases RNAi Innovations at Upcoming Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is set to highlight its advancements in RNA interference (RNAi) therapeutics through a series of presentations at prominent healthcare conferences in December 2024. The company participates in the Piper Sandler 36th Annual Healthcare Conference on December 3, where it hosts a fireside chat at 1:30 p.m. EST. This event serves as a platform for Arrowhead to discuss its innovative approaches to treating various diseases using RNAi technology. Following this, Arrowhead also engages attendees at the 7th Annual Evercore ISI HealthCONx Conference with another fireside chat on December 4 at 2:10 p.m. EST, further solidifying its commitment to advancing healthcare solutions.

A significant focus of Arrowhead’s presentations will be on its Phase 3 study, PALISADE, which evaluates the efficacy and safety of Plozasiran in adults at risk of Acute Pancreatitis due to Familial Chylomicronemia Syndrome (FCS). This study represents a critical step in addressing the challenges faced by patients with FCS, a rare genetic disorder that can lead to severe health complications. Arrowhead’s participation in the APA/JPS/CAP/IAP 2024 Joint Meeting on December 9 at 12:00 p.m. HST will provide an opportunity to share insights and data from this pivotal study, emphasizing the company's focus on developing targeted therapies for intractable diseases.

In addition to the PALISADE study, Arrowhead Pharmaceuticals will present on the development of small interfering RNA (siRNA) therapies for neurodegenerative disorders at the 8th Complement-Based Drug Development Summit on December 11 at 10:00 a.m. EST. This presentation underscores Arrowhead's commitment to exploring novel applications of RNAi technology beyond metabolic disorders. The company will also share findings from the PALISADE study at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on December 13. Arrowhead Pharmaceuticals continues to position itself as a leader in the RNAi space, aiming to revolutionize treatment paradigms for complex diseases.

As Arrowhead Pharmaceuticals prepares for these conferences, it invites stakeholders and interested parties to access presentation materials on its website, under the Investors section. This strategic engagement not only showcases the company's innovative research but also enhances its visibility within the biopharmaceutical industry. For continuous updates, stakeholders can follow Arrowhead on X (formerly Twitter) at @ArrowheadPharma.